Skip to main content

Table 2 Clinical findings of patients underwent ASCT

From: The miRNA 196a2 rs11614913 variant has prognostic impact on Turkish patients with multiple myeloma

   Patients Controls
  N:156 (%) N:200 (%)
Age    55 (28–72) 53 (22–68)
Gender Female/Male   75/81 (48/52) 99/101 (50/50)
Diagnosis agea (years)    55 (28–72)  
Ig subtypes κ/λ   88/40 (68/32)  
  G/A   84/20 (66/16)  
  Light chain   24 (18)  
Stage (Salmon-Durie) II/III   53/89 (38/62)  
  A/B   97/31 (76/24)  
ISS I   42 (33)  
  II/III   35/52 (28/41)  
ECOG >1   12/127 (9.4)  
Hemoglobin gr/dL 10.4 (6.2–15)   
White blood cell count /μL 6980 (2700–18,500)   
Platelet count 103/μl 162 (61–406)   
C-reactive protein mg/dl 7.4 (2.1–352)   
LDH IU/l 208 (93-1037)   
β2-microglobulin mg/l 4.9 (1.5–47)   
Albumin g/l 3.5 (1.6–5.1)   
Treatment VCd, AHSCT, Rd   156 (100)  
OS (5 years)  %   79   
PFSa   55.3   
Mortality    25 (16)  
Follow-up period a(month)   36 (7.8-155)   
  1. AHSCT Autologous hematopoietic stem cell transplantation, VCd Bortezomib, Cyclophosphamide, dexamethasone, Rd Lenolidomide, dexamethasone, ECOG Eastern Cooperative Oncology Group, Ig Immunglobulin, LDH Lactate dehydrogenase, ISS internationale stage system, OS overall survival, PFS Progression free survival
  2. amedian